ClinicalTrials.gg
CompletedNCT02332499ALTER0703Updated May 21, 2019

Study of Anlotinib in Patients With Metastatic Colorectal Cancer(mCRC)(ALTER0703)

A Phase 2/3 interventional study of Anlotinib and Placebo in Metastatic Colorectal Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Completed at 29 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-05-21.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
419
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing anlotinib in Colorectal Neoplasms — 2 open to participants now, 4 under way, 1 of them phase 3. anlotinib · Colorectal Neoplasms.

Enrollment
2nd of 10
419 · median 46
Started
2014
the only one that year
Phase 2/3
Only one
of the 10
Registered
1st of 10
by date
Lead sponsor
3 of 10
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Among the 10 studies testing anlotinib in Colorectal Neoplasms, this one is the 2nd largest by enrollment, is the only one that started in 2014, is the only one in phase 2/3, and was the 1st registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

2 of the 10 studies testing anlotinib in Colorectal Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About anlotinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing anlotinib in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to compare the effects and safety of Anlotinib with placebo in patients with metastatic colorectal cancer refractory to standard chemotherapies.

Read the detailed description

Anlotibib (AL3818) is a kind of innovative medicines approved by State Food and Drug Administration(SFDA:2011L00661) which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd.To compare the effects and safety of Anlotinib with placebo in patients with metastatic colorectal cancer refractory to standard chemotherapies.

03

Conditions studied

  • Metastatic Colorectal Cancer

Keywords

  • Anlotinib
  • Metastatic Colorectal Cancer (mCRC)
  • ALTER0703
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed and dated ;
  2. Histological or cytological documentation of adenocarcinoma of the colon or rectum;
  3. Subjects with colorectal cancer (Stage IV),With (using RECIST1.1);
  4. Progression during or within 3 months following the last administration of approved standard therapies which must include Fluorouracil or its derivatives, Oxaliplatin, Irinotecan;
  5. PS:0-1, of more than 3 months;
  6. main organs function is normal;
  7. main organs function is normal;

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with Anlotinib;
  2. Major surgical procedure, open , or significant traumatic injury within 28 days before start of study drug;
  3. Known ;
  4. patients with severe and failed to controlled diseases;
  5. patients occurred venous thromboembolic events within 6 months;
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
419 participants (actual)

Study arms

  • Active comparator
    Anlotinib

    Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent

    Drug: Anlotinib

  • Placebo comparator
    Placebo

    Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent

    Drug: Placebo

Interventions

  • Anlotinib p.o. qd

    Also known as: AL3818

  • DrugPlacebo

    Placebo p.o. qd

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Time frame: From randomization until death (up to 24 months)

Secondary outcomes

  1. Progress free survival (PFS)

    Time frame: each 42 days up to PD or death(up to 24 months)

  2. Objective Response Rate (ORR)

    Time frame: each 42 days up to intolerance the toxicity or PD (up to 24 months)

  3. Disease Control Rate (DCR)

    Time frame: each 42 days up to intolerance the toxicity or PD (up to 24 months)

  4. Number of Participants with Adverse Events as a Measure of Safety and Tolerability

    Time frame: Until 30 day safety follow-up visit

07

Study locations

29 sites
  • The 1st Affiliated Hospital of Bengbu Medical College
    Bengbu, Anhui, China
  • The Second Affiliated Hospital, Anhui Medical University
    Hefei, Anhui, China
  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    Beijing, Beijing 100021, China
  • Peking Union Medical College Hospital
    Beijing, Beijing, China
  • The 307th Hospital of Chinese People's Liberation Army
    Beijing, Beijing, China
  • Chongqing Cancer Hospital
    Chongqing, Chongqing, China
  • The Second Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing, China
  • Fujian Cancer Hospital
    Fuzhou, Fujian, China
  • Gansu Province Tumor Hospital
    Lanzhou, Gansu, China
  • The First Affiliated Hospital of Sun Yat-sen university
    Guangzhou, Guangdong, China
  • The Sixth Affiliated Hospital of Sun Yat-sen university
    Guangzhou, Guangdong, China
  • Guangxi medical university affiliated tumor hospital
    Nanning, Guangxi, China
  • Harbin medical university affiliated tumor hospital
    Haerbin, Heilongjiang 150000, China
  • The Second xiangya Hospital of Central South University
    Changsha, Hunan, China
  • The First People's Hospital of Lianyungang
    Lianyungang, Jiangsu, China
  • Jiangsu Cancer Hospital
    Nanjing, Jiangsu, China
  • Jiangsu Province Hospital
    Nanjing, Jiangsu, China
  • Nantong Cancer Hospital
    Nantong, Jiangsu, China
  • Jiangxi Cancer Hospital
    Nanchang, Jiangxi, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi, China
  • Jilin Cancer Hospital
    Changchun, Jilin, China
  • Liaoning Province Tumor Hospital
    Shenyang, Liaoning, China
  • Qilu Hospital,Shandong University
    Jinan, Shandong, China
  • Cancer Hospital of Fudan University
    Shanghai, Shanghai, China
  • Shanxi Cancer Hospital
    Xian, Shanxi, China
  • Tangdu Hospital of The fourth Military Medical University
    Xian, Shanxi, China
  • The First Affiliated Hospital of Xian Jiaotong University
    Xian, Shanxi, China
  • Tianjin Medical University Cancer Hospital
    Tianjin, Tianjin, China
  • The First Affiliated Hospital of Zhejiang University
    Hangzhou, Zhejiang, China
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2014, a primary completion of Aug 2016 and a completion of Mar 2019. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 31, 2014
First posted
Jan 6, 2015
Start
Dec 2014
Primary completionActual
Aug 18, 2016
CompletionActual
Mar 1, 2019
Last update
May 21, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02332499
Responsible party
Sponsor
First posted
Jan 6, 2015
Start date
Dec 2014
Primary completion
Aug 18, 2016
Completion
Mar 1, 2019
Last update
May 21, 2019

Study contacts

Yihebali Chi, doctor
principal investigator · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Jianqiang Cai, doctor
principal investigator · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Jinwan Wang, doctor
principal investigator · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anlotinib

Start the discussion